Selpercatinib (Retevmo)
Targeted TherapyApproved for: NSCLCBiomarker: RET Selpercatinib (Retevmo) is a FDA-approved treatment for non-small cell lung cancer (NSCLC) that has a RET fusion gene and is metastatic. It is used in adults. Related Research News Estimated Lung Cancer Screening Rates...